Article Text

Download PDFPDF

#982 Pressurized intraperitoneal aerosol chemotherapy (PIPAC) evaluation of safety and feasibility in advanced ovarian cancer. experience of an oncological expert center
  1. Blanca Valenzuela-Méndez,
  2. Alix Bouillin,
  3. Gonzalo Guiñez-Robertson,
  4. Guillaume De Meeus,
  5. François Quénet and
  6. Olivia Sgarbura
  1. Cancer Institute of Montpellier, Montpellier, France


Introduction/Background Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is an innovative drug delivery system for peritoneal metastases with enhanced pharmacological benefits. This therapy may be an option for the treatment of symptoms of advanced ovarian cancer, contributing to improve survival and quality of life of patients. We aim to study the feasibility and safety of this therapy in patients with advanced ovarian cancer.

Methodology A prospectively PIPAC database was retrospectively analyzed from January 2016 to December 2022. All patients who underwent PIPAC for advanced ovarian cancer were selected. Epidemiologic and clinical data were analyzed.

Results 28 patients underwent 52 PIPAC in the Oncology Institute of Montpellier. The median age was 65 (63–68 years), 96.4% high-grade serous histology, with a median number of chemotherapy lines of 2 (2–3) and a platinum sensitivity of 59.3%. The overall group mortality is 82.1%, with a median survival after treatment initiation of 166 (113–264) days. The median procedure time was 91.5 (79.8–103) minutes and a median hospital stay of 3 days. The complication rate was 12%, all grade I-II, with a 30-day mortality of 0%. In the subgroup with more than 2 PIPACS we observed a lower mortality 76.9% vs. 86.7% and a higher survival (209 vs. 115) which, although not significant, is reflected in the Kaplan Meyer survival curve.

Abstract #982 Table 1

Demographic and clinical characteristics of the total group. Data are presented as median (IQR); values expressed as percentages (%) indicate the proportion in the total group.

Conclusion PIPAC in advanced ovarian cancer is feasible, safe, and well tolerated. Its oncological utility as well as its indications in patients with advanced ovarian cancer remain to be determined.

Disclosures The authors have no conflicts of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.